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Abstract 
 
Heart failure is a common disease with high levels of morbidity and mortality.  
Current treatment comprises of beta-blockers, ACE inhibitors, aldosterone 
antagonists and diuretics. Variation in clinical response seen in patients begs the 
question of whether there is a pharmacogenetic component yet to be identified.   
To date, the genes most studied involve the beta-1, beta-2, alpha-2 adrenergic 
receptors, and the renin-angiotensin-aldosterone pathway, mainly focusing on single 
nucleotide polymorphisms (SNPs). However results have been inconsistent. Genome 
wide association studies (GWAS) and next generation sequencing (NGS) are seen 
as alternative approaches to discovering genetic variations influencing drug 
response.  
It it hoped thatHopefully future genetics research will lay the foundations for 
genotype-led drug management in patients with heart failurethese patients with the 
ultimate aim of improving their response and clinical outcome. 
 
 
 
Executive Summary 
 Heart failure is a common cause of hospitalisation and its incidence is set to 
rise. 
 Mainstay of treatment comprise of beta blockers, ACE inhibitors, aldosterone 
antagonists, and diuretics. 
 Single nucleotide polymorphisms (SNPs) potentially influencing drug 
response include the Arg 389 Gly variant and the Ser 49 Gly variant in the 
beta 1 adrenergic receptor, the Arg 16 Gly, Gln 27 Glu and Thr 164 Ile 
polymorphisms within the beta 2 adrenergic receptor, an insertion at the 
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287th base pair in the angiotensin converting enzyme and the Gly 264 Ala 
mutation in the sodium-chloride co-transporter.  
 Next generation sequencing (NGS) and systems biology approach might 
provide better alternatives of understanding the underlying disease process of 
heart failure.  
 
Introduction 
Heart failure (HF) is one the most common cause of hospitalisation and represents 
the end stage of a variety of heart conditions; it is associated with significant 
morbidity and mortality (1-2).  Prognosis is poor, with 1-year mortality estimates 
ranging between 25-45%. Furthermore its incidence is rising and with an ageing 
population, this disease is likely to increase in importance in its impact of the 
healthcare burden (3-5). The pathophysiology of HF is centred on increased activity 
in the adrenergic and renin-angiotensin-aldosterone systems (RAAS), which leads to 
vasoconstriction and fluid restriction with further deleterious effect on cardiac 
function. Beta-blockers, ACE inhibitors/ angiotensin II receptor blockers and 
aldosterone antagonists reduce activity in these pathways and have shown 
prognostic benefit, thus are the foundation of HF therapy (6-12).   
HF mortality remains high in spite of numerous validated randomised controlled trials 
(RCT) to guide HF management but meta-analysis of these RCTs relating to B-
blocker therapy has shown varying treatment response, correlated with cohort 
geographical location (5,13). To account for this varying treatment response, firstly it 
is worth appreciating that the underlying HF aetiology has been shown to affect drug 
response in HF and beyond this, ethnicity, gender, body mass index, renal function 
are likely implicated (14-16). But genetic polymorphisms manipulating drug response 
may also account for these findings (17-21).  
In the past decade there has been considerable progress in cardiovascular 
pharmacogenetics, with genetic determinants defined for both warfarin and 
clopidogrel leading to alteration of product label for these drugs, suggesting the use 
of genetic information to guide therapy (22-23).  There is a growing body of evidence 
that variation in proteins within the sympathetic axis and RAAS influence drug 
response thus increasingly pharmacogenetics of HF research is being sought as a 
way to optimise HF treatment and advance new drug development in this area (24-
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31). Although drug response variation in HF is likely multi-factorial, pharmacogenetic 
variation may partially account for therapeutic failure contributing to the remaining 
high mortality in HF. Identifying novel gene variants affecting treatment response 
may reveal unrecognised pathways and new potential therapeutic targets. Few 
studies to date have attempted to assess the extent to which variation in drug-
response was exclusively due to genetic factors and therefore expounding the likely 
clinical benefit of using pharmacogenetics to guide HF therapy. One of the 
prerequisites to bridging this gap is to consider likely trial designs and criteria that will 
lead to a consensus upon using pharmacogenetics-based variants to guide therapy 
in clinical practice. 
We will review the current key body of evidence on pharmacogenetics candidate 
genes for HF and the challenges and framework required to advance the goal of 
pharmacogenetics based HF therapy. 
  
Pharmacogenetics and heart failure: candidate genes 
Antagonism of Renin- angiotensin-aldosterone system (RAAS) 
Enhanced RAAS activity augments afterload and cardiac workload with subsequent 
adverse ventricular remodelling leading to worsening cardiac failure making RAAS 
inhibition a fundamental of HF therapy.  ACE inhibitors, angiotensin 2 receptor 
blockers and aldosterone antagonists have been shown to reduce mortality and 
promote reversal of cardiac remodelling (8,12,32). The “I/D” single nucleotide 
polymorphism (SNP) variant in the ACE gene (referring to presence or absence of an 
insertion at the 287th base pair), with DD genotype are over three times as likely to 
have raised plasma aldosterone in a dose dependent manner, despite long term 
treatment with ACE inhibitors (31).  A prospective study into the ‘I/D’ variant in 479 
HF subjects with systolic dysfunction found the D variant was associated with worse 
transplant free survival at 1 year (89% survival in II, 80% ID, 74% DD). Furthermore it 
was also showed that the negative effect of the D allele was most evident in subjects 
on low dose ACE inhibitors or not taking beta-blockers and was negated by high 
dose ACE inhibitors (21). This is one of the few studies to date to have attempted to 
assess the extent to which variation in drug-response was exclusively due to an 
SNP. Despite this compelling evidence for interaction between ACE I/D SNP and 
ACE inhibitor dose on survival with the authors postulating a combined use of ACE 
inhibitors and angiotensin II receptor blockers may benefit DD homozygotes, it has 
not translated to genotyping at this locus to influence prescribing. 
On top of this, the negative effect of the D allele was greater in those not taking beta-
blockers and other studies have shown that sympathetic stimulation increased 
sympathetic response in subjects with the Arg389 allele and relatively increased 
plasma renin. These findings suggest neuro-hormonal interactions are important and 
considering genotypes across these two systems may allow more effective tailoring 
of HF therapy (33). Notwithstanding the good evidence for a drug-gene interaction 
that is more consistent than any other loci in this setting, ACE I/D genotyping still 
does not guide ACE inhibitor prescription.  The ‘bench to bedside’ link remains 
elusive, clinicians remain either unaware or unconvinced of how genetic variation 
could influence ACE inhibitor response.  Framework for establishing such a link is 
detailed later. From a pragmatic perspective, patients whose genotype infers benefit 
from high-dose inhibitors can only do so if their renal function permits. This illustrates 
that pharmacogenetics can only be useful in guiding heart failure therapeutics as part 
of a wider picture.     
The adrenergic system 
Reduced cardiac output in HF promotes increased sympathetic activity via the alpha-
mediated vasoconstriction leading to an increase in total peripheral resistance and 
activation of beta adrenergic receptors increasing chronotropy and inotropy. This  
subsequently results in  increased wall tension, myocyte necrosis, oxygen demand 
and is dysrhythmogenic. The understanding of this pathophysiology and RCTs on B-
blockers (metoprolol, bisoprolol and carvedilol) that have shown beneficial effect on 
survival and disease progression have formed the cornerstone of HF treatment (6-7, 
9-10, 34). Most of the research on pharmacogenetics in heart failure focuses on 
response/outcomes with B-blocker therapy. The key SNPs relating to this system will 
be discussed followed by the clinical impacts of these SNPs at the end. 
 
Beta 1 adrenergic receptor (B1AR) 
B1AR is a major pathologic β-adrenergic subtype in heart failure. Gene variants in 
B1AR may influence beta-blocker response as there is a varying degree of response 
seen among the different subsets of heart failure patients despite receiving the same 
class of drug. The polymorphisms Arg 389 Gly and Ser 49 Gly are the most studied, 
with allele frequencies for both SNPs estimated around 50-70% and 15-20% 
respectively. Although other SNPs have been found in relation to B1AR, the allele 
frequencies are <1% and thus not likely to be of public health significance (35).  
The potential role of the Arg 389 Gly polymorphism in reducing mortality was seen in 
a genetic substudy of the B-blocker evaluation of Survival Trial (BEST) (28). The trial 
was prematurely terminated at 2 years due to a lack of mortality benefit overall, 
however non-blacks who were more likely to carry the Arg 389 Gly polymorphism 
had a significantly improved mortality (28). The genetic substudy demonstrated that 
those who were Arg 389 homozygotes had a 34% mortality benefit with bucindolol 
and this was supported with ex-vivo cell data (29). This apparent mortality benefit of 
bucindolol in Arg 389 homozygotes was initially attributed to the added property of 
bucindolol in reducing noradrenaline levels in the body but the benefit was still 
demonstrated in a subset of patients who had stable noradrenaline levels, lending 
support to the hypothesis of enhanced beta-blockade effect as a benefit mechanism 
(28). Unfortunately the lack of consistency of this effect across large clinical trial data 
and the relatively small difference in allele frequencies between the racial groups 
suggest alternative explanations for racial differences in beta-blocker response rather 
than purely due to SNP Arg 389 (29). 
At a molecular level, the SNP Arg 389 Gly is associated with greater agonist-
promoted G protein coupling, making it the more active form of the receptor, this was 
elucidated by looking at dobutamine response in 10 healthy Arg 389 homozygotes 
and 8 Gly 389 homozygotes (35). Arg 389 homozygosity is associated with enhanced 
chronotropy, contractility and bisoprolol more effectively reduced sympathetic 
response. Furthermore Arg 389 homozygotes showed increased plasma renin 
activity suggesting neuro-hormonal cross-talk is also important (33), thus in this 
instance structural changes here apparently have the expected effect. 
The Ser 49 Gly variant was investigated using left ventricular myocytes from HF 
patients, since cAMP is the second messenger in beta 1 stimulated signal 
transduction, this was used as a marker for agonist response in cells with Gly 49 
versus Ser 49.  This study found basal and agonist stimulated cAMP levels were 
greater in cells with the Gly 49 variant, which showed greater desensitisation and 
receptor down-regulation with saturating catecholamine levels, this may account for 
improved survival in HF patients carrying Gly 49 (36-37).  Despite this, there is 
inconsistent evidence that this translates to differences in drug response.  
Downstream, G-protein receptor kinases (GRKs) phosphorylate B1ARs and B2ARs, 
reducing agonist-promoted receptor function promoting desensitization. The main 
cardiac GRKs are GRK2 and GRK5, screening identified 4 relevant genetic variants 
in the GRK 5 gene, but none in GRK2 (20).  The Gln 41 Leu SNP is the most studied 
variant in the GRK 5 gene, this SNP is represented in the GRK5 regulatory domain.  
The Leu 41 variant is uncommon in Caucasians but is carried by up to 40% of African 
Americans, HF appears to develop independently of carrying the Leu 41 variant but it 
may convey survival benefit in established HF (38).  Interestingly the Leu 41 variant 
is more prevalent in Takotsubo cardiomyopathy sufferers suggesting associated 
susceptibility to sudden adrenergic rushes (39).  
  
Beta 2 adrenergic receptors 
Beta 2 adrenergic receptor (B2AR) gene variation may also be important, three 
potentially functionally significant SNPs identified include: Arg 16 Gly, Gln 27 Glu and 
Thr164 Ile.  The Arg 16 Gly and Gln 27 Glu polymorphisms, represented in the 
extracellular amino terminus, are in linkage disequilibrium. Animal studies of the Gly 
16 variant was associated with a reduction in agonist promoted down-regulation, 
while the Glu 27 variant was correlated with complete resistance to down-regulation 
(40).  The Thr 164 Ile polymorphism is represented within the proposed ligand-
binding pocket, it exists purely in the heterozygous state and is in linkage 
disequilibrium with Gly 16 and Glu 27 (41-42).  Cells expressing Ile 164 in vitro 
displayed lower binding affinity for adrenaline, suggesting attenuated in vivo 
response (41). Ile 164 may be associated with a reduced response to B2AR 
mediated vasodilatation, potentially accounting for why carriers had reduced HF 
survival rates. Higher phenylephrine doses were required to induce 50% dilatation in 
the dorsal hand vein for Thr 164 carriers whilst higher doses of isoproterenol were 
required in Ile 164 carriers (43).  Subsequent work showed B2AR mediated 
vasodilatation depended on complex inter-play between the above 3 SNPs (44).  
  
Alpha adrenergic receptors (A2ARs). 
A2ARs influence blood pressure via central and peripheral mechanisms, and studies 
suggesting variation in response to alpha adrenergic agonists may have a genetic 
component have focused on deletion of three glutamic acid residues at base pairs 
301-303 in the A2AR.  A2AR del 301-303 variant may effect desensitisation, 
facilitating attenuation of chronically increased vascular tone with increased 
sympathetic activity in HF but other studies have not been able to demonstrate that 
del 301-303 predicts variability in A2AR mediated vasoconstriction (45-46).  
 
Another example of polymorphisms affecting the alpha adrenergic receptors is seen 
in the ADRA2c gene which encodes the α2CAR receptor. Regulation of noradrenaline 
levels via a negative feedback mechanism is controlled by the α2CAR receptor and a 
multiple-nucleotide polymorphism α2c322-325 deletion (Del) here has been 
associated with increased heart failure in black patients (29).  
 
Clinical Significance of Adrenergic system Genetic Variants on Therapeutic 
Response and Outcome 
Do these genetic variants modulate therapeutic benefit in HF patients?   Initial 
studies showed Arg 389 Gly and Ser 49 Gly in the B1AR gene and Glu 27 Gln in the 
B2AR gene influenced beta-blocker response in HF patients, also showing greater 
improvement in echocardiographic parameters with beta-blockers than Gly 389, Ser 
49 and Gln 27 carriers (27, 47-48). Homozygous carriers of Gln 27 in HF sufferers 
respond less well to carvedilol than Glu 27 carriers (18-19).  Subsequently it was 
postulated that B2ARs expressing Gln 27 were sensitive in vitro but ‘pre-
desensitised’ in vivo by chronic endogenous agonist exposure.  B2ARs expressing 
the Gln 27 variant may have reduced desensitization in vitro, potentially explaining in 
vitro desensitization resistance with Gln 27 (40,49-50). 
On the contrary, other studies failed to show a drug-gene interaction with the above 
variants.  A sub-study from the MERIT HF trial (9) showed the Arg 389 variant did not 
predict outcome with either placebo or metoprolol (51), although notably the 2 
treatment arms were not compared by genotype. Thus whether Gly 389 carriers 
benefitted less from metoprolol than Arg 389 homozygotes is unknown.  De Groote et 
al also found no difference in beta-blocker response correlated with any of the above 
genetic variants for the B1AR and B2AR gene in assessing change of heart rate and 
ejection fraction among HF patients (52).   
These discrepancies may due to the above studies only involving a relatively small 
sample size, which may not yield statistically meaningful results given the rarity of 
some of the variants studied (see Table 1).  Also combining adrenergic receptor 
genetic variants may be more fruitful than individual polymorphisms, one study 
addressed this by dividing heart failure patients into 2 groups: one including those 
who were Arg 389 homozygous with at least one copy of the Gly 27 variant and the 
second included all other genotypes.  The first group had shorter survival with 
carvedilol than the second group, although there was no difference with metoprolol 
(53).  
 
Genetic variation in GRK may influence beta-blocker response. One study 
demonstrated in African American HF sufferers not on beta-blockers, Leu 41 
conveyed a survival advantage mimicked by beta blockade (20).  This suggests that , 
genotyping here could avoid needless side effects and cost from patients taking a 
drug unlikely to be beneficial.  However, few other studies have looked at drug-gene 
interaction here.   
Given these inconsistent results and insufficient studies, it is unsurprising that usage 
of genotyping to guide beta-blocker prescription has not materialised.  Despite the 
above research, relatively few clinicians are aware of the genetic variations 
influencing beta-blocker response. Therefore the case for the clinical value of 
pharmacogenetics in HF is fragile since no consensus exists on whether these 
variants consistently predict drug response.  
 
Nitric oxide 
Nitric oxide regulates myocardial remodelling, vascular reactivity and thrombosis 
(54).  The hydralazine/isosorbide dinitrate (H/IDN) combination releases nitric oxide, 
reducing vascular tone.  Interest in genetic variation in nitric oxide synthase (NOS) 
was initiated from V-HeFT study, which showed African American patients had better 
survival rates on H/IDN whilst Caucasian did better on ACE inhibitors (55). This 
prompted the AHeFT study: a double-blind trial of 1050 African Americans with heart 
failure NYHA class III-IV randomized to H/IDN or placebo, mortality was significantly 
higher in the placebo group (54).  
SNPs may account for racial difference in drug response.  One study investigated 
genetic variation in NOS 3 as the Glu 298 variant is more common in black patients. 
There was a significant improvement in quality of life in patients taking H/IDN with the 
Glu 298 variant and a trend towards LV reverse remodelling and no trend was 
evident with other genotypes (56).  H/IDN was licensed for use in black patients with 
HF but controversy regarding racially-guided drug prescribing ensued. H/IDN was 
infrequently prescribed and the manufacturers discontinued production (57).  This 
was arguably racially-guided therapy rather than personalised medicine, although it is 
cheaper and more cost-effective to direct therapy based on race rather than 
genotype, by overlooking the social context of prescribing and not pursuing biological 
accuracy the end result was counter productive for personalised medicine. 
 
Renal sodium transporter and response to loop diuretics 
Although diuretic prescription is common in HF patients yet significantly less is known 
regarding pharmacogenetics involved here.  Reasons why two clinically similar 
patients require widely differing loop diuretic doses evade us (59).  One study looked 
at genetic variation in renal sodium transporters, measuring excretion of sodium, 
potassium, chloride and volume of urine in 97 healthy subjects taking bumetanide, 
torasemide and furosemide to identify differences related to genotype. The SLC12A3 
Ala 264 polymorphism in the sodium-chloride co-transporter gene was associated 
with increased excretion of potassium and chloride ions with all loop diuretics.  
Similar trends towards stronger excretion were also seen with sodium, calcium and 
volume of urine excreted (60), but the significance of how this applies to HF patients 
is unknown so there is currently no prospect of genotyping here guiding HF 
therapeutics.    
  
Novel positional candidates: discovered through GWAS  
Genome wide association studies (GWAS) provide a mechanism for discovering 
relevant genetic loci and have identified drug-gene interactions in treatment of other 
cardiovascular diseases (61-62).  To date virtually no published GWAS has sought 
relevant genes in HF drug response, GWAS have been used to identify loci 
implicated in the development of HF and outcome in patients with HF (63-65).  
Candidate gene studies are intrinsically limited, investigators can only hope to find an 
association between the specific genes examined and the outcome measured since 
any of the 2.5 million SNPs coded for may be significant.  This method may yield new 
pathological pathways, potentially pointing towards new treatment targets.  To date, 
there are limited GWAS looking for genetic variants associated with heart failure that 
have been published (66-67).  Norton and colleagues carried out exome sequencing 
on a large family with DCM, discovering a mutation in the heat-shock protein BAG3 
was correlated with heart failure (64,66).  Smith and colleagues on the other hand, 
identified 2 loci that were associated with the development of heart failure among 
those of African and European descent (63 – 65). Another study carried out a 
population-based GWAS comparing patients with HF with controls and discovered 
new susceptibility loci in HSPB7 and FRMD4B (67).   
The only GWAS investigating HF pharmacogenomics was performed in a canine 
model of heart failure, where the investigators aim to discover SNPs predictive of 
beta-blocker response. Three SNPs reached genome wide significance, one was 
located within the MRPS10 gene, which encodes a small subunit of mitochondrial 
ribosomes, and variation here could logically influence myocardial energetics 
(68). This was a tentative first step towards using GWAS to identify variants 
influencing drug response in HF. Using GWAS to identify novel loci in HF 
pharmacogenomics has broad potential but this is largely unchartered territory and 
careful analysis will be required upon emergence of new SNPs.   This may be partly 
due to the known pitfalls with GWAS, including the high false discovery rate and the 
need to replicate any findings in a second, large clinical study (69). Furthermore, 
although GWAS may identify a specific locus, it does not identify the specific variant 
or combination of variants within the locus that exert biological effects (25). 
As we might expect, SNP analysis is time consuming and has some limitations. 
There is a frequent finding of false positives and and it is unable to reliably analyse 
rare variants, and gene-gene interactions. We do not yet understand the exact 
biological function of most SNPs that are discovered and one SNP alone does not 
always translate into a clinically relevant pharmacogenetic loci as there is often a lot 
of other genetic interactions involved.  
A potential alternative approach is the utilisation of next generation sequencing 
(NGS). This involves millions of small fragments of DNA which can all be sequenced 
at the same time. Whole exomes can be analysed and this will provide a large 
amount of data. NGS has the advantage of looking at large amounts of  genetic data 
in a shorter perios of time, and will be able to identify complex haplotypes, gene-gene 
interactions and rare variants in order to identify a novel pharmacogenetic loci. A 
potential problem however is the large amount of data that needs to be handled at 
any one time.  
 An potential alternative approach which has shown promise is the utilisation of next 
generation sequencing (NGS).  
Non-genetic factors influencing drug tailoring  in heart failure 
As suggested earlier ethnic variation in heart failure therapeutic response is unlikely 
to be exclusively genetic, Bloche wrote a comprehensive analysis of the VHeFT and 
AHeFT studies and highlighted the importance of psychosocial, environmental, 
cultural and economic factors that may  influence ethnic difference in response to 
heart failure therapy, further noting that research  has neglected these areas (70).  
One study found social isolation was associated with greater vascular resistance in 
response to perceived stressors and impaired repair mechanisms, such as wound 
healing (71).  
No studies to date have attempted to estimate the proportion of drug-response 
variability that may be due to genetic variation versus environmental factors in 
clinically similar patients.  Also differences in pharmacokinetics and 
pharmacodynamics should be considered, as Roden et al points out, any 
physiological variable impacting the interaction with a drug or its receptor can 
modulate drug action, e.g. catecholamine levels affect drug-adrenergic receptor 
interaction (23). 
Another area gaining momentum is tailoring medication in response to biomarker 
levels as there is considerable evidence for the relationship between brain natriuretic 
peptide (BNP) levels and worse prognosis in those with HF (72-73).  A recent meta-
analysis looked at six trials in which patients with HF were randomized to titration of 
their medical therapy according to circulating BNP levels or a parallel control group 
(total n=1 627).  All six studies showed mortality benefit in the BNP-guided therapy 
group compared to controls and no studies reported increased incidence of adverse 
effects in this group (74).  Therefore eventually it may be possible to use a 
combination of pharmacogenetics and biomarker levels to guide HF therapy, which 
could further optimise the therapeutic benefit (75). Investigation into the proteomics 
of HF may also reveal variation that can be used to guide HF therapy hand-in-hand 
with biomarkers and pharmacogenomics, which would facilitate bridging the gap of 
genotype and phenotype.  Disparity between genotype and phenotype may also 
account for the inconsistent results with current SNPs, further appreciation of this 
relationship would be a significant step forward.  Although, research into proteomic 
variation in HF is largely at the animal model stage, there are preliminary data that 
show that proteomics may offer promise in determining outcome in HF (76 – 77) 
 
 
 
Future directions and consensus building 
Pharmacogenetics already guides therapy for oncological use of biological agents 
and assays determining TPMT activity guide azathioprine prescription (78-79).  It 
should also be possible to implement pharmacogenetics into practice with HF 
therapies. A major obstacle to clinically implementing HF pharmacogenetic 
discoveries has been the inconsistent results; hence stronger evidence for specific 
drug-gene interactions is needed.  GWAS discovery has been used in over 250 
human traits, which includes disease susceptibility, physical attributes and serum 
biomarkers (80).  Global collaboration is needed to gain suitably powered study 
samples. The genomics of drug response in HF requires both retrospective analysis 
of randomized-control trials where DNA has been collected and observational studies 
where genomic information is linked to medical records in a large population to 
provide robust estimates of the genetic architecture of the drug response traits.  One 
such large observational study has already been initiated (81).  
Any genetic algorithm proposed for predicting drug response must be shown to be 
efficacious in randomised, prospective studies.  Flynn proposes confirmatory trial 
designs for pharmacogenetic studies including targeted and stratification designs 
(82).  In the targeted design, patients are genotyped at screening and those with the 
genotype being studied are included and randomised to one of the treatment groups, 
restricting results to one genotype. Varying drug effects across different genotypes 
may be investigated using the stratification design, where patients are allocated to 
groups based on genotype then randomized to treatment. Notably both designs 
require considerable prior knowledge of the genetic marker. Even though targeted 
and stratification studies provide methods for translating pharmacogenetic knowledge 
into prescribing guidance, they do not address the interplay of how different genetic 
combinations influence drug-response.  Although a version of the stratification design 
may be useful, this would be increasingly difficult as more complex genetic and 
therapeutic criteria determine which group a patient is allocated to, as number of 
subjects per group will fall, reducing statistical power.  
Several genetically guided HF drug-trials are being devised.  In 2010, ARCA 
Biopharma (Bloomfield, CO) and the FDA agreed on a safety and efficacy trial of 
bucindolol versus metoprolol CR/XL in 3200 patients homozygous for B1AR Arg38 
(83).  Also a study evaluating the impact of genetic variations on candesartan 
response in approximately 300 HF patients already on an ACE inhibitor has been 
completed, results are awaited (84).  
Studying patients with HF to determine whether a specific genetic variant is 
protective or deleterious in HF patients taking certain drugs is fraught with difficulties, 
given the multi-factorial causation of variation of drug response.  Individuals with HF 
recruited into these studies are likely to have less severe disease or subject the 
results to survivor bias (85). Reduction of survivor bias may be possible by storing 
genotypic information in an electronic medical record and making this data available 
at the time of drug prescription.  Roden et al’s pre-emptive approach would allow 
‘automated delivery of point-of-care decision support’ (23) and appears to be a 
pragmatic proposal as part of establishing the bench to bedside link.       
  
The challenges to population-wide implementation of pharmacogenetic discoveries 
were highlighted with CYP2C19 and clopidogrel and CYP2C9 / VKORC1 and 
warfarin (86-87).  Although, the US FDA added pharmacogenomics labels to 
clopidogrel and warfarin, existing challenges include the required threshold of 
evidence to translate it into practice and the demonstration of an increased value 
above the current functional testing practices (88-89).  Additionally, newer agents 
may be used instead of warfarin and clopidogrel, potentially without the same 
requirement for genetic stratification (90-92), but have been associated with 
increased bleeding.  In this regard, a recent study has shown the benefits of point of 
care testing of CYP2C19 in the choice between anti-platelet agents clopidogrel and 
prasugrel (93). 
 
Although functional assays may help guide prescription of specific drugs (94) there 
are no functional tests available to guide and monitor efficacy for HF therapies at 
present.  Low-cost genome sequencing of patients at disease diagnosis may be 
more beneficial.  Storing whole genome information from the time of diagnosis would 
allow systematic annotation of the patient’s medical record with appropriate 
pharmacogenomic information.  If this information was accessible at the point of 
prescription it could be used to guide the use of multiple drugs across different 
diseases. Physicians would not have to know about, commission or await results of a 
specific test before making prescribing decisions. But the challenges of reducing the 
cost of genome sequencing and developing the infrastructure to support this decision 
making process remain to be fully addressed. 
In 2005 the US FDA approved the use of isosorbide dinitrate and hydralazine 
combination for HF treatment in African-Americans and this approach of race-
targeted drug development is not without its flaws. Race is a difficult concept in the 
21st century as its definition is becoming more homogenous as the world becomes 
more globalised. There are ethical questions surrounding this approach and 
accepting that race alone influences the course of a disease ignores the other 
economics and socio-cultural factors at play.  
   
Currently, despite many studies looking for variants influencing drug therapy in HF, 
this has not been applied clinically.  There is little prospect of this changing in the 
immediate future given the inconsistent results to date. But the approach outlined 
here may be the initial step towards improving the process of deriving evidence for 
pharmacogenetics based HF therapy. It is important to note that HF is a 
heterogeneous trait and multiple factors beyond genetic variability influence drug 
response in HF, as described above.  Comorbidities and HF aetiology are particularly 
pertinent when considering how to tailor HF therapy to the individual.  Respiratory 
and renal comorbidities are particularly important in HF as they may limit the dose of 
beta-blockers and ACE inhibitors that may be used, regardless of whether the 
patient’s genotype suggests higher doses would be beneficial (95-99).   
Finally, the recent systems biology approach that takes into account the integration of 
genes and molecules, as well as interpreting the relationship between molecular 
units and the corresponding mechanical counterparts will hopefully be able to better 
increase our understanding of  heart failure and help us develop effective therapy 
(100). Through the construction of mathematical models and simulation, systems 
biology allows us to integrate the information from fields such as genomics and 
proteomics with clinical-epidemiological data and provide better understanding of the 
disease process in HF (101). 
   
 
      
  
 
 
Conclusion 
Mounting evidence suggests drug-gene interactions influence treatment with all 
agents used in heart failure therapeutics.  The GWAS approach may help identify 
more loci, with potential for new drug development. Expansion upon current evidence  
using the above methods, results of which may ultimately be the foundation for 
tailoring of HF therapy to an individual’s genome and clinical profile helping to 
minimize side effects including improvement in cost-effectiveness.  Disappointingly, 
there are no short term prospects of widely employing genetically guided HF 
therapy.  Given current trends, HF cases are likely to continue to increase over the 
coming years, making the enhancement of HF therapeutics’ more important than 
ever.    
  
 
Table 1:  Summary of  most studied genetic variants in the pharmacogenetics of heart failure, including 
the minor allele frequencies values and rs ID if available,  taken from Database of Single Nucleotide 
Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National 
Library of Medicine. (dbSNP Build ID: 
  
  
 
 
 
Receptor/ transporter Genetic Variant Minor allele 
frequency; 
rsID 
Pharmacogenetic association 
A2AR Del 301-303 n/a Deletion associated with resistance to desensitization (38) 
ACE Insertion/ deletion (I/D) n/a Deletion associated with raised serum ACE (20) 
B1AR Arg 389 Gly 0.304;  
rs1801253 
Arg form gain-of-function allele 
Associated with enhanced response to bucindolol(27) 
B1AR Ser 49 Gly 0.173;  
rs1801252 
Gly 49 associated with enhanced desensitisation and agonist-
promoted down-regulation (28) 
B2AR Thr 164 Ile 0.005;  
rs1800888 
Ile 164 loss of function allele, attenuated response to 
sympathetic stimulation (35) 
B2AR Gln 27 Glu 0.234;  
rs1042714 
Gln 27 associated with reduced response to 
carvedilol (13, 14) 
B2AR Arg 16 Gly 0.474;   
rs1042713 
Arg 16 loss of function variant; shorter duration 
stimulation (41). 
Reduced response to beta blockade (89). 
GRK5 (acts on B1AR 
and B2AR) 
Gln 41 Leu 0.087;  
rs17098707 
Leu 41 gain of function allele 
Associated with improved survival in patients not on 
beta-blockers (15) 
NOS 3 Asp 298 Glu 0.196;  
rs1799983 
Glu 298 associated with good response to H/ IDN (53) 
Renal sodium 
transporter 
SLC12A3 Ala 264 n/a Associated with enhanced excretion potassium and 
chloride (50) 
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